CERUS CORP: ARK Investment Management LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
ARK Investment Management LLC amended its Schedule 13G filing for Cerus Corp., updating its beneficial ownership stake in the blood-safety technology company with the SEC under accession number 0001104659-26-126824. The filing reflects ARK's current position in Cerus, a company whose shares are tied to the rollout of its INTERCEPT blood system. Investors watch 13G amendments for signals of whether major institutional holders are adding to or trimming positions. The amended filing did not disclose a change in share count in the headline notice.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
ARK Investment Management LLC, Cerus Corp